Intensive chemotherapy provided the longest overall and progression-free survival, especially in blast phase MPN patients. Venclexta-based treatments did not significantly improve progression-free ...
in AML in its ongoing Phase 1/2a EVICTION study The FDA designed Fast Track status to facilitate the development and expedite the review of therapeutic candidates that have the potential to treat ...
in AML in its ongoing Phase 1/2a EVICTION study “The growing body of data on ICT01 together with the FDA’s Fast Track designation further validates our development of ICT01 in first-line AML patients ...
Management of newly diagnosed acute myeloid leukemia (AML) in patients deemed unfit for intensive chemotherapy is undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback